ERBB2 and ovarian carcinoma: An open-label phase II trial (NCT04482309)- DESTINY-PanTumor02 was conducted to evaluate the efficacy and safety of T-DXd in 267 patients, including 40 ovarian cancer patients with select HER2-expressing solid tumors that were locally advanced, metastatic, or inoperable.